Cargando…
Gut microbiota and cardiovascular disease: opportunities and challenges
Coronary artery disease (CAD) is the most common health problem worldwide and remains the leading cause of morbidity and mortality. Over the past decade, it has become clear that the inhabitants of our gut, the gut microbiota, play a vital role in human metabolism, immunity, and reactions to disease...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7071638/ https://www.ncbi.nlm.nih.gov/pubmed/32169105 http://dx.doi.org/10.1186/s40168-020-00821-0 |
_version_ | 1783506247670038528 |
---|---|
author | Kazemian, Negin Mahmoudi, Morteza Halperin, Frank Wu, Joseph C. Pakpour, Sepideh |
author_facet | Kazemian, Negin Mahmoudi, Morteza Halperin, Frank Wu, Joseph C. Pakpour, Sepideh |
author_sort | Kazemian, Negin |
collection | PubMed |
description | Coronary artery disease (CAD) is the most common health problem worldwide and remains the leading cause of morbidity and mortality. Over the past decade, it has become clear that the inhabitants of our gut, the gut microbiota, play a vital role in human metabolism, immunity, and reactions to diseases, including CAD. Although correlations have been shown between CAD and the gut microbiota, demonstration of potential causal relationships is much more complex and challenging. In this review, we will discuss the potential direct and indirect causal roots between gut microbiota and CAD development via microbial metabolites and interaction with the immune system. Uncovering the causal relationship of gut microbiota and CAD development can lead to novel microbiome-based preventative and therapeutic interventions. However, an interdisciplinary approach is required to shed light on gut bacterial-mediated mechanisms (e.g., using advanced nanomedicine technologies and incorporation of demographic factors such as age, sex, and ethnicity) to enable efficacious and high-precision preventative and therapeutic strategies for CAD. |
format | Online Article Text |
id | pubmed-7071638 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-70716382020-03-18 Gut microbiota and cardiovascular disease: opportunities and challenges Kazemian, Negin Mahmoudi, Morteza Halperin, Frank Wu, Joseph C. Pakpour, Sepideh Microbiome Review Coronary artery disease (CAD) is the most common health problem worldwide and remains the leading cause of morbidity and mortality. Over the past decade, it has become clear that the inhabitants of our gut, the gut microbiota, play a vital role in human metabolism, immunity, and reactions to diseases, including CAD. Although correlations have been shown between CAD and the gut microbiota, demonstration of potential causal relationships is much more complex and challenging. In this review, we will discuss the potential direct and indirect causal roots between gut microbiota and CAD development via microbial metabolites and interaction with the immune system. Uncovering the causal relationship of gut microbiota and CAD development can lead to novel microbiome-based preventative and therapeutic interventions. However, an interdisciplinary approach is required to shed light on gut bacterial-mediated mechanisms (e.g., using advanced nanomedicine technologies and incorporation of demographic factors such as age, sex, and ethnicity) to enable efficacious and high-precision preventative and therapeutic strategies for CAD. BioMed Central 2020-03-14 /pmc/articles/PMC7071638/ /pubmed/32169105 http://dx.doi.org/10.1186/s40168-020-00821-0 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Review Kazemian, Negin Mahmoudi, Morteza Halperin, Frank Wu, Joseph C. Pakpour, Sepideh Gut microbiota and cardiovascular disease: opportunities and challenges |
title | Gut microbiota and cardiovascular disease: opportunities and challenges |
title_full | Gut microbiota and cardiovascular disease: opportunities and challenges |
title_fullStr | Gut microbiota and cardiovascular disease: opportunities and challenges |
title_full_unstemmed | Gut microbiota and cardiovascular disease: opportunities and challenges |
title_short | Gut microbiota and cardiovascular disease: opportunities and challenges |
title_sort | gut microbiota and cardiovascular disease: opportunities and challenges |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7071638/ https://www.ncbi.nlm.nih.gov/pubmed/32169105 http://dx.doi.org/10.1186/s40168-020-00821-0 |
work_keys_str_mv | AT kazemiannegin gutmicrobiotaandcardiovasculardiseaseopportunitiesandchallenges AT mahmoudimorteza gutmicrobiotaandcardiovasculardiseaseopportunitiesandchallenges AT halperinfrank gutmicrobiotaandcardiovasculardiseaseopportunitiesandchallenges AT wujosephc gutmicrobiotaandcardiovasculardiseaseopportunitiesandchallenges AT pakpoursepideh gutmicrobiotaandcardiovasculardiseaseopportunitiesandchallenges |